Clinical Trial Update: A Study to Evaluate the Safety and Efficacy of BIIB104 in Participants With Cognitive Impairment Associated With Schizophrenia (CIAS) [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating BIIB104 for cognitive impairment associated with schizophrenia has completed enrollment and results were posted in 2023.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cognitive Impairment Associated with Schizophrenia

Drugs mentioned

• BIIB104 (BIIB104)

Snippet

Sponsor: Biogen | Conditions: Cognitive Impairment Associated With Schizophrenia | Phase 2 | Status: COMPLETED | Results posted: 2023-04-18